Literature DB >> 9520009

A 7 minute neurocognitive screening battery highly sensitive to Alzheimer's disease.

P R Solomon1, A Hirschoff, B Kelly, M Relin, M Brush, R D DeVeaux, W W Pendlebury.   

Abstract

OBJECTIVE: To determine the validity and reliability of a rapidly administered neurocognitive screening battery consisting of 4 brief tests (Enhanced Cued Recall, Temporal Orientation, Verbal Fluency, and Clock Drawing) to distinguish between patients with probable Alzheimer's disease (AD) and healthy control subjects.
SUBJECTS: Sixty successive referrals to the Memory Disorders Clinic at Southwestern Vermont Medical Center, Bennington, who were diagnosed as having probable AD and 60 community-dwelling volunteers of comparable age, sex distribution, and education.
DESIGN: Interrater and test-retest reliability, intergroup comparisons between patients with AD and control subjects on the 4 individual tests, and determination of probability of dementia for patients with AD and control subjects using the entire battery of tests.
SETTING: Outpatient care. MAIN OUTCOME MEASURE: Comparison of the probability of dementia on the 7 Minute Screen with the criterion standard of clinical diagnosis established by examination and laboratory studies. SECONDARY OUTCOME MEASURES: Test-retest and interrater reliability (correlation coefficients), time for administration.
RESULTS: Mean time of administration was 7 minutes 42 seconds. Mean scores for patients with AD and control subjects on all 4 individual tests were significantly different (for each, P<.001). When the 4 tests were combined in a logistic regression, the battery had a sensitivity of 100% and a specificity of 100%. A series of 1000 repeated random samples of 30 patients with AD and 30 control subjects taken from the overall sample of 60 patients with AD and 60 control subjects had a mean sensitivity of 92% and a mean specificity of 96%. The battery was equally sensitive to patients with mild AD as demonstrated by correctly classifying all 13 patients with AD using Mini-Mental State Examination scores of 24 or higher. Neither age nor education was a statistically significant factor when added as a covariate. Test-retest reliabilities for individual tests ranged from 0.83 to 0.93. Test-retest reliability for the entire battery was 0.91. Interrater reliability for the entire battery was 0.92.
CONCLUSIONS: The 7 Minute Screen appears highly sensitive to AD and may be useful in helping to make initial distinctions between patients experiencing cognitive changes related to the normal aging process and those experiencing cognitive deficits related to dementing disorders such as AD. It has reasonable interrater and test-retest reliability, can be administered in a brief period, and requires no clinical judgment and minimal training.

Entities:  

Mesh:

Year:  1998        PMID: 9520009     DOI: 10.1001/archneur.55.3.349

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  72 in total

Review 1.  MicroCog: assessment of cognitive functioning.

Authors:  R W Elwood
Journal:  Neuropsychol Rev       Date:  2001-06       Impact factor: 7.444

2.  The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia.

Authors:  E F J Meulen; B Schmand; J P van Campen; S J de Koning; R W Ponds; P Scheltens; F R Verhey
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

3.  Scenery Picture Memory Test: a new type of quick and effective screening test to detect early stage Alzheimer's disease patients.

Authors:  Hajime Takechi; Hiroko H Dodge
Journal:  Geriatr Gerontol Int       Date:  2010-04       Impact factor: 2.730

4.  Initial screening of patients for Alzheimer's disease and minimal cognitive impairment.

Authors:  Edmund Howe
Journal:  Psychiatry (Edgmont)       Date:  2007-07

5.  Paradoxical recovery in a bilingual patient with aphasia after right capsuloputaminal infarction.

Authors:  A García-Caballero; I García-Lado; J González-Hermida; R Area; M J Recimil; O Juncos Rabadán; S Lamas; G Ozaita; F J Jorge
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01       Impact factor: 10.154

Review 6.  A review of screening tests for cognitive impairment.

Authors:  Breda Cullen; Brian O'Neill; Jonathan J Evans; Robert F Coen; Brian A Lawlor
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-18       Impact factor: 10.154

7.  Dementia: What pharmacists need to know.

Authors:  Silvia Duong; Tejal Patel; Feng Chang
Journal:  Can Pharm J (Ott)       Date:  2017-02-07

8.  Individualized evaluation of cholinesterase inhibitors effects in dementia with adaptive cognitive testing.

Authors:  Hans Wouters; Jos P C M Van Campen; Bregje A Appels; Jos H Beijnen; Aeilko H Zwinderman; Willem A Van Gool; Ben Schmand
Journal:  Int J Methods Psychiatr Res       Date:  2015-08-24       Impact factor: 4.035

9.  Visual association test to detect early dementia of the Alzheimer type.

Authors:  J Lindeboom; B Schmand; L Tulner; G Walstra; C Jonker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

Review 10.  Understanding memory dysfunction.

Authors:  Andrew E Budson
Journal:  Neurologist       Date:  2009-03       Impact factor: 1.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.